Posted by Michael Wonder on 26 Sep 2022
Janssen's Imbruvica passes reimbursement review, BeiGene's Brukinsa fails
22 September 2022 - Janssen's Imbruvica (ibrutinib) and BeiGene's Brukinsa (zanubrutinib), the two BTK (Bruton tyrosine kinase) inhibitors with the same mechanism, received two different review results from the HIRA cancer drug reimbursement review committee.
The review panel granted expanded reimbursement for the first generation BTK inhibitor, Imbruvica, as the first-line monotherapy to treat chronic lymphocytic leukaemia/small lymphocytic lymphoma.
